Bicalutamide

Catalog No.S1190 Synonyms: ICI-176334

Bicalutamide Chemical Structure

Molecular Weight(MW): 430.37

Bicalutamide is an androgen receptor (AR) antagonist with IC50 of 0.16 μM in LNCaP/AR(cs)cell line.

Size Price Stock Quantity  
In DMSO USD 109 In stock
USD 120 In stock
USD 210 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 16 Publications

5 Customer Reviews

  • Immunohistochemical staining of Ki67 was performed to determine cell proliferation in the tumors. Each tissue section was counted manually in three different areas to assess the Ki67-positive cell index. Data were then presented as number of Ki67-positive cells per x 400 microscope field. Results are presented as the means s.d. **P < 0.001 by Student 's t-test, compared with control.

    Oncogene 2014 10.1038/onc.2014.302. Bicalutamide purchased from Selleck.

  • When Tramp-C1 and PTENCaP8 cells were cocultured with macrophages and treated with BMP-6 and dihydrotestosterone simultaneously for 48 h, AR antagonists bicalutamide (Bical) and MDV3100 blocked the androgen hypersensitivity.

    Cancer Sci 2013 104(8), 1027-32. Bicalutamide purchased from Selleck.

  • CX4945 resensitizes CRPC cells to anti-androgen therapy. a, b 22Rv1 and VCaP cells were treated with indicated concentration of bicalutamide (Bic) without CX4945. c, d 22Rv1 and VCaP cells were treated with indicated concentration of bicalutamide (Bic) with a subdose of CX4945 (3 or 5 μM). CCK8 assay was performed at 72 h to measure the cell viability. **P < 0.01, ***P < 0.001

    World J Urol, 2017, 35(8):1213-1221. Bicalutamide purchased from Selleck.

  • Cancer Res, 2018, doi:10.1158/0008-5472.CAN-17-3728. Bicalutamide purchased from Selleck.

  • (D) Cell apoptosis measured by flow cytometry analysis after cells were exposed to 10μM bicalutamide and 10μM ABT-888 alone or in combination for 48h in MDA-MB-231 and HCC1937. Data are the mean of three independent experiments. *P<0.05, **P<0.01, #P>0.05.

    Int J Biol Sci, 2016, 12(12):1500-1510. Bicalutamide purchased from Selleck.

Purity & Quality Control

Choose Selective Androgen Receptor Inhibitors

Biological Activity

Description Bicalutamide is an androgen receptor (AR) antagonist with IC50 of 0.16 μM in LNCaP/AR(cs)cell line.
Targets
Androgen Receptor [1]
(LNCaP/AR(cs) cells)
0.16 μM
In vitro

Bicalutamide undergoes an antagonist-to-agonist switch, stimulating AR activity. Bicalutamide treatment of LNCaP/AR(cs) cells in absence of the synthetic androgen R1881 results in altered gene expression consistent with its well-documented agonist activity in context of AR overexpression. Bicalutamide induces cell proliferation in a dose-dependent manner, and only partially antagonized the effects of R1881. Bicalutamide treatment also results in a significant amount of nuclear AR, although less than that observed with R1881. Bicalutamide exhibits partial agonist activity as evidenced by induction of DNA binding at AR target genes and incomplete antagonism of the effects of R1881. In absence of R1881, Bicalutamide partially activates VP16-AR–mediated transcription, indicative of AR binding to DNA. In LNCaP/AR-luc cells with a stably integrates AR-driven luciferase reporter construct. In the presence of R1881, Bicalutamide shows only weak partial antagonism of VP16-AR–mediated transcription with an IC50 of 0.35 μM. [1] Micromolar bicalutamide causes a significant dose-dependent reduction in clonogenicity. [2] Dual inhibition of the AR and mTOR signaling pathways provides further benefit with the ridaforolimus-bicalutamide combination producing syner -gistic antiproliferative effects in prostate cancer cells in vitro when compared with each agent alone. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MDA-MB-453 cells Mn[4SpVv[3Srb36gZZN{[Xl? NV3MZmxQTGm|cHzhZ4Vu\W62IH;mJHs{UF2UMUi4NUBnem:vIFHSJIlvKGi3bXHuJG1FSS2PQj20OVMh[2WubIOsJGVEPTB;M{Ggcm0> Mo\pNlM4OTN3Nke=
LNCaP cells M4XVc2Z2dmO2aX;uJIF{e2G7 MkPSTY5pcWKrdHnvckBw\iCdM1jdMWRJXCCkaX7kbY5oKHSxIGS4O|dCKGGwZILv[4VvKHKnY3XweI9zKG:oIFzOR4FRKGOnbHzzMEBMcT1|NTDuUS=> M2P5XVE2PjB|OU[w
Freestyle293F cells Mn70SpVv[3Srb36gZZN{[Xl? M{TzN2lvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFHu[JJw\2WwIILlZ4VxfG:{IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGZz\WW|dIns[VI6O0ZiY3XscJMtKEmFNUC9NE4xPTRizszN NFXp[2YzOzF7OUS3Oy=>
HEK293 cells NIjvUWdHfW6ldHnvckBie3OjeR?= NGPQdVE{KGh? M371UWRqe3CuYXPlcYVvfCCxZjDbNVcu[WyyaHGtcYV1cHmuLUPIYY1q[m:uZYLvcoUh\nKxbTDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHHmeIVzKDNiaILzMEBKSzVyPUW0JI5O MW[yNlM6OTB|Mx?=
MDA453 cells MlXiSpVv[3Srb36gZZN{[Xl? NWj0WHV5TGm|cHzhZ4Vu\W62IH;mJHs{UF2GSGSg[pJwdSCqdX3hckBidmS{b3flckBz\WOncITvdkBqdiCPRFG0OVMh[2WubIOsJGtqRTZ2IH7N NHvDZ2kyQDJ7MU[0OC=>
human MDA-MB-453 cells MnO0SpVv[3Srb36gZZN{[Xl? NFrsN4tFcXOybHHj[Y1mdnRib3[gX|NJZUSKVDDmdo9uKEGUIHnuJIh2dWGwIF3ERU1OSi12NUOgZ4VtdHNuIFnDOVA:PjRibl2= NWnx[GxEOjB3OES2NVA>
COS1 cells MYjGeY5kfGmxbjDhd5NigQ>? NEPoVphCdnSjZ3;ubZN1KGGldHn2bZR6KGGpYXnud5QheFOJNT30ZYdo\WRiaIXtZY4h[W6mcn;n[Y4hemWlZYD0c5Ih\XiycnXzd4VlKGmwIFPPV|Eh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIILlZ4VxfG:{LX3l[IlifGWmIITyZY5{[3KrcITpc45idCCjY4Tpeol1gSCkeTDBVk1z\We3bHH0[YQhemG2IIDyc4Jie2mwIIDyc41wfGW{IH\yZYdu\W62IHTybZZmdiCoaYLl[ox6KGy3Y3nm[ZJie2VicnXwc5J1\XJiYYPzZZktKEmFNUC9NE4xQDZ7IN88US=> NHW2VoIzPTZ2Nk[0PS=>
HeLa cells MkfZSpVv[3Srb36gZZN{[Xl? NImwemVCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IHj1cYFvKGGwZILv[4VvKHKnY3XweI9zKGW6cILld5Nm\CCrbjDI[WxiKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[g[IlpgWS{b4Tld5Rwe3Sncn;u[UBqdmS3Y3XkJJRz[W6|Y4LpdJRqd26jbDDhZ5Rqfmm2eTDifUBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwQVAvOTRizszN NUnEdY5JOTd6MESyNlk>
CV1 cells MmPSSpVv[3Srb36gZZN{[Xl? Mo\XRolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hS1ZzIHPlcIx{NCCNaU2wMlE2OSEQvF2= Mn7lNVczPTd6M{i=
monkey COS7 cells MWPGeY5kfGmxbjDhd5NigQ>? MofORolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hdW:wa3X5JGNQWzdiY3XscJMh[nlid3jvcIUh[2WubDDibY5lcW6pIHHzd4F6NCCNaU2wMlE2OSEQvF2= NXfQOIhnOTh2NEK5NVI>
COS7 cells NXGwS|k{TnWwY4Tpc44h[XO|YYm= NYq4RlF3SWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBidmS{b3flckBz\WOncITvdkBYPzRzQzDteZRidnRiZYjwdoV{e2WmIHnuJGNQWzdiY3XscJMh[XO|ZYPz[YQh[XNibIXjbYZmemG|ZTDhZ5Rqfmm2eTDh[pRmeiB{NDDodpMh[nlicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkG4JO69VQ>? NYH2NXg3OjJyOUSyO|k>
CHO-K1 cells M1PKOWZ2dmO2aX;uJIF{e2G7 M1z4[lIhcA>? M3\tXWRqe3CuYXPlcYVvfCCxZjDbN2hedWmkb3zldo9v\SCocn;tJIh2dWGwIFHSJIV5eHKnc4Pl[EBqdiCFSF:tT|Eh[2WubIOgZYZ1\XJiMjDodpMh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whUUN3ME2wMlIh|ryP MlXvNlA{QDF|NkG=
human HT-3 cell MkXnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkTLTY5pcWKrdHnvckBw\iCqdX3hckBJXC1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63N|E{PCEQvF2= MVjTRW5ITVJ?
human LNCAP cells M4[3XXBzd2yrZnXyZZRqd25iYYPzZZk> MWOzJIRigXN? MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEyQQ1HQJINmdGy|IHHmeIVzKDNiZHH5d{whUUN3ME2wMlc{OjdizszN NHr3[Y4zPjB2NkOxNy=>
human PC3 cells NX\XUYRPTnWwY4Tpc44h[XO|YYm= M{jr[WRqe3CuYXPlcYVvfCCxZjDbN2heWjF6OEGg[pJwdSCjbnTyc4dmdiC{ZXPldJRweiCrbjDoeY1idiCSQ{OgZ4VtdHNuIFXDOVA:PC5|IN88US=> M4\OTFI2PTlzME[2
human 22Rv1 cells M37ZdmZ2dmO2aX;uJIF{e2G7 NGLz[4o{KGSjeYO= MWnBcpRi\2:waYP0JIFkfGm4aYT5JIF1KGGwZILv[4VvKHKnY3XweI9zKEh6N{TZJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBpfW2jbjCyNnJ3OSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGRJXC2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHHmeIVzKDNiZHH5d{BjgSCZU2StPEBie3OjeTygTWM2OD12Lk[g{txO MViyOFkxODV6OB?=
human CCF-STTG1 cell M3XtOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1vnNGlvcGmkaYTpc44hd2ZiaIXtZY4hS0OILWPUWGcyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XoxvJygTWM2OD12LkmyPVI6KM7:TR?= MUjTRW5ITVJ?
human SCC-25 cell NW\rfXVJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmfKTY5pcWKrdHnvckBw\iCqdX3hckBUS0NvMkWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlA5PjV4IN88US=> MkHkV2FPT0WU
human MKN45 cell NXPNfXVFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnPpTY5pcWKrdHnvckBw\iCqdX3hckBOU052NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uPVYxPSEQvF2= MkTsV2FPT0WU
human ES5 cell M{TQb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml32TY5pcWKrdHnvckBw\iCqdX3hckBGWzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD16Lk[xNVU1KM7:TR?= MX7TRW5ITVJ?
human SK-MEL-3 cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX[5eIN{UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFyLkC5OlQh|ryP NGLQ[2ZUSU6JRWK=
human PC-3 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnrnTY5pcWKrdHnvckBw\iCqdX3hckBRSy1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUCuNlc6OSEQvF2= NVj1VYd3W0GQR1XS
human NOS-1 cell M33NbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MW\Jcohq[mm2aX;uJI9nKGi3bXHuJG5QWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUGuNlkyPyEQvF2= MVLTRW5ITVJ?
human LB1047-RCC cell NGW5[WFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{iyWGlvcGmkaYTpc44hd2ZiaIXtZY4hVEJzMES3MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF{LkK1N{DPxE1? MX7TRW5ITVJ?
human CAMA-1 cell M3G3Zmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWHN[3NZUW6qaXLpeIlwdiCxZjDoeY1idiCFQV3BMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOi5|OUK2JO69VQ>? MVrTRW5ITVJ?
human SAS cell M3HuXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYjsR5pRUW6qaXLpeIlwdiCxZjDoeY1idiCVQWOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xN{4{ODhzIN88US=> MkfOV2FPT0WU
human NCI-H2228 cell NGK5dFBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVzH[ohvUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIzOjhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMz63OVMyKM7:TR?= MonOV2FPT0WU
human NCI-H187 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mlr2TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG4O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE3NjZ4MU[g{txO MVfTRW5ITVJ?
human BFTC-905 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV;lb5BFUW6qaXLpeIlwdiCxZjDoeY1idiCERmTDMVkxPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF5LkS4OVch|ryP NIG5c2tUSU6JRWK=
human G-361 cell M1f1dmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWW4NZd1UW6qaXLpeIlwdiCxZjDoeY1idiCJLUO2NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE4Njh{NjFOwG0> MYrTRW5ITVJ?
human DU145 cells NGrXbXlEgXSxdH;4bYPDqGG|c3H5 M3fFeFczKGh? NUPUbIVOS3m2b4TvfIlkcXS7IHHnZYlve3RiRWLhcJBp[S2mZX\pZ4lmdnRiaIXtZY4hTFVzNEWgZ4VtdHNiZYjwdoV{e2mwZzDFVoJmfGFiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zODFOwG0> NH7KXFVUSU6JRWK=
human SW780 cell NXzEVo5QT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnfJTY5pcWKrdHnvckBw\iCqdX3hckBUXzd6MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5 MWnTRW5ITVJ?
human BB49-HNC cell NFq3XFNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHX2eZRKdmirYnn0bY9vKG:oIHj1cYFvKEKENEmtTG5EKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OThwOUWzNkDPxE1? NIT4bmJUSU6JRWK=
human KALS-1 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGTO[HZKdmirYnn0bY9vKG:oIHj1cYFvKEuDTGOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE6NjZ4M{Wg{txO M4SzcXNCVkeHUh?=
human AU565 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXzJcohq[mm2aX;uJI9nKGi3bXHuJGFWPTZ3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUmuO|QxOiEQvF2= M1LFcXNCVkeHUh?=
human NCI-H2087 cell NEOyTmVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUHsTI1EUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxQDdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{MT6wOVkyKM7:TR?= NUi2Uo9lW0GQR1XS
human RVH-421 cell MnnMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYfJcohq[mm2aX;uJI9nKGi3bXHuJHJXUC12MkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNU42Pzl3IN88US=> NIC5XodUSU6JRWK=
human SK-CO-1 cell NIX3b3hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH3iOnVKdmirYnn0bY9vKG:oIHj1cYFvKFONLVPPMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zOS56OEeyJO69VQ>? Mmm2V2FPT0WU
human KU-19-19 cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIn1b4JKdmirYnn0bY9vKG:oIHj1cYFvKEuXLUG5MVE6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjJwMEK0NkDPxE1? M3T0S3NCVkeHUh?=
human NB6 cell NVq3UJBTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFrKRXdKdmirYnn0bY9vKG:oIHj1cYFvKE6ENjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKyMlkyOzVizszN MXTTRW5ITVJ?
human RO82-W-1 cell MlOwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1PBTmlvcGmkaYTpc44hd2ZiaIXtZY4hWk96Mj3XMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zOy5zM{G4JO69VQ>? Mnz1V2FPT0WU
human LNCAP cells NWrOZ|hNS3m2b4TvfIlkyqCjc4PhfS=> M3fCbVIh\GG7cx?= NUnpZY81S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVE6FQWCgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhOiCmYYnzJIJ6KGOnbHygZ492dnSrbnegcYV1cG:mLDDJR|UxRTJ|Lke5JO69VQ>? NUXp[21IOjN5MkewOFQ>
human CTB-1 cell M{XnPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWTTWVQ4UW6qaXLpeIlwdiCxZjDoeY1idiCFVFKtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI1NjV3M{[g{txO MWHTRW5ITVJ?
human SW48 cell Mnv1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlHBTY5pcWKrdHnvckBw\iCqdX3hckBUXzR6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkSuOlU1PiEQvF2= NX62bYFWW0GQR1XS
human TCCSUP cell NUntZnBiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M13oSWlvcGmkaYTpc44hd2ZiaIXtZY4hXEOFU2XQJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlQvPzJ|MjFOwG0> MYjTRW5ITVJ?
human DK-MG cell M3fjdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1SxZWlvcGmkaYTpc44hd2ZiaIXtZY4hTEtvTVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yOE45QTF5IN88US=> NUPsOIllW0GQR1XS
human ST486 cell NXjvNXQ3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUHhOndOUW6qaXLpeIlwdiCxZjDoeY1idiCVVES4OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI2Njd2NkSg{txO NWq5[pNqW0GQR1XS
human H4 cell NUW4N2xMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVHJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjZwOUS1PEDPxE1? M4fLW3NCVkeHUh?=
human SBC-1 cell MnTpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYHLPWZwUW6qaXLpeIlwdiCxZjDoeY1idiCVQlOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI5NjN3MEeg{txO NY\xbJZLW0GQR1XS
human CAS-1 cell NEi4fXNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXrJcohq[mm2aX;uJI9nKGi3bXHuJGNCWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkiuOlI6PCEQvF2= MVzTRW5ITVJ?
human OAW-42 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWPJcohq[mm2aX;uJI9nKGi3bXHuJG9CXy12MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK4MlcyQTVizszN NFz0VFRUSU6JRWK=
human HCC1954 cell Moe2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVnJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF7NUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yPE44PTJ3IN88US=> NVm4TYI1W0GQR1XS
human MDA-MB-453 cell M{PKeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGTlSWpKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk01PTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{OT65NFch|ryP NI\id2VUSU6JRWK=
human MCF7 cell NX\LVlBFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFHOZZBKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zPU4{ODFizszN NIn6OmtUSU6JRWK=
human PC3 cells MnTuSpVv[3Srb36gZZN{[Xl? M4TaRVExOOPCgN88US=> NIPyb|g1QCCq M{XI[GlvcGmkaYTpc44hd2ZiYXP0bY4h[mG|ZXSgdJNmfWSxcH;kbYEh\m:{bXH0bY9vKGmwIHHu[JJw\2WwLXTldIVv\GWwdDDoeY1idiCSQ{OgZ4VtdHNiYYSgNVAxKHWPIHHmeIVzKDR6IHjyd{BjgSCGQWDJJJN1[WmwaX7nJIJie2WmIH\seY9z\XOlZX7j[UBucWO{b4Pjc5B6KGG|c3H5 MYmyNlY4Ojl6NB?=
human PC3 cells MoGwSpVv[3Srb36gZZN{[Xl? NFnqUFExNjFvMTFOwG0> M3r4bGFod26rc4SgZYN1cX[rdImgZZQh[W6mcn;n[Y4hemWlZYD0c5IhXzd2MVOgcZV1[W62IHX4dJJme3OnZDDpckBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhe3SrbYXsZZRqd25ib3[gdoVk\XC2b4KgeJJidnOjY4TpeoF1cW:wIHH0JFAvOSC2bzCxJJVOKGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfS=> NVOzUnNlOjJzN{W2PVQ>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Cytosolic AR / Nuclear AR ; 

PubMed: 30833616     


The representative expressions and the quantifications of proteins regarding the bicalutamide-induced apoptosis. (a) downregulation of nuclear androgen receptor (nAR).

30833616
Growth inhibition assay
Cell viability; 

PubMed: 27994514     


MDA-MB-231 and HCC1937 cells were treated with 10 μM bicalutamide and 10μM ABT-888 alone or in combination for 24h, 48h, 72h, and cell viability was determined by MTT assay.

27994514
In vivo Single bicalutamide reduces tumor growth by 79%, at defined submaximal doses. The ridaforolimus-bicalutamide combination exhibits improved and potent antitumor activity, almost completely abrogating tumor growth. The combination is also well tolerated, as evidenced by no significant changes in body weight over the course of treatment. Plasma PSA levels are again tightly linked to tumor growth in the combination-treated mice. [3]

Protocol

Kinase Assay:[1]
- Collapse

Whole-cell competitive binding assays:

Whole-cell competitive binding assays are performed in LNCaP/AR(codon-switch) (LNCaP/AR(cs)) (harbors a mixture of exogenous wild-type AR and endogenous mutant AR (T877A)) and cells propagated in Iscove's or RPMI media supplemented with 10% fetal bovine serum, or during the assay with 10% charcoal-stripped, dextran-treated fetal bovine serum (CSS). Cells are pre-incubated with 18F-FDHT, increasing concentrations (1pM to 1μM) of cold Bicalutamide are added, and the assay is performed to measure specific uptake of 18F-FDHT (4). IC50 values are determined using a one site binding model with least squares curve fitting and R2 > 0.99.
Cell Research:[3]
- Collapse
  • Cell lines: C4-2 cell
  • Concentrations: 0-1 μM
  • Incubation Time: 72 hours
  • Method: Exponentially growing C4-2 cells are plated into two 96-well plates and incubated overnight at 37 ˚C. Twenty-four hours later one plate is aspirated and stored at -80 ˚C and the other treated with 10-fold serial concentrations of ridaforolimus (1000 nM to 0.0001 nM) or vehicle (ethanol). Following 72 hours culture at 37 ˚C, the plates are assessed simultaneously for cell growth using the Cy qUANT Cell Proliferation Assay kit. Bicalutamide and Ridaforolimus combination proliferation assays are performed similarly except cell growth is determined as the change in cell number between vehicle control and compound treated cells after 72 hours in culture.
    (Only for Reference)
Animal Research:[3]
- Collapse
  • Animal Models: Male nude mice bearing C4-2 cells
  • Formulation: 4% ethanol, 5% Tween 80, and 5% propylene glycol
  • Dosages: 10 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL (199.82 mM)
Ethanol 5 mg/mL (11.61 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 430.37
Formula

C18H14F4N2O4S

CAS No. 90357-06-5
Storage powder
in solvent
Synonyms ICI-176334

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02910050 Recruiting Drug: Bicalutamide|Drug: Aromatase Inhibitor Breast Cancer Xu fei|Sun Yat-sen University January 2016 Phase 2
NCT02614859 Recruiting Drug: Bicalutamide|Drug: Metformin and Bicalutamide Cancer of Prostate Fox Chase Cancer Center|National Cancer Institute (NCI) December 1 2015 Phase 2
NCT02146937 Withdrawn Drug: Bicalutamide plus Finasteride- Combination therapy Detectable Prostate Nodules Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins March 2014 Phase 2
NCT01415778 Completed Drug: ICI176334-1|Drug: Casodex 80 mg tablet Healthy AstraZeneca August 2011 Phase 1
NCT01415791 Completed Drug: ICI176334-1 Healthy AstraZeneca August 2011 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Androgen Receptor Signaling Pathway Map

Related Androgen Receptor Products

Tags: buy Bicalutamide | Bicalutamide ic50 | Bicalutamide price | Bicalutamide cost | Bicalutamide solubility dmso | Bicalutamide purchase | Bicalutamide manufacturer | Bicalutamide research buy | Bicalutamide order | Bicalutamide mouse | Bicalutamide chemical structure | Bicalutamide mw | Bicalutamide molecular weight | Bicalutamide datasheet | Bicalutamide supplier | Bicalutamide in vitro | Bicalutamide cell line | Bicalutamide concentration | Bicalutamide nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID